These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 34052705)
21. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients. Takeoka H; Yamada K; Naito Y; Matsuo N; Ishii H; Tokito T; Azuma K; Ichiki M; Hoshino T Anticancer Res; 2018 Jun; 38(6):3779-3784. PubMed ID: 29848743 [TBL] [Abstract][Full Text] [Related]
22. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751 [TBL] [Abstract][Full Text] [Related]
23. A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit. Khosravi A; Salimi B; Esfahani-Monfared Z; Seifi S; Mirtavoos-Mahyari H Asian Pac J Cancer Prev; 2018 Oct; 19(10):2973-2978. PubMed ID: 30362335 [TBL] [Abstract][Full Text] [Related]
24. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562 [TBL] [Abstract][Full Text] [Related]
25. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424 [TBL] [Abstract][Full Text] [Related]
27. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503 [TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China. Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285 [TBL] [Abstract][Full Text] [Related]
29. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Spigel DR; Hainsworth JD; Joseph MJ; Shipley DL; Hagan MK; Thompson DS; Burris HA; Greco FA Cancer; 2018 May; 124(9):1982-1991. PubMed ID: 29451696 [TBL] [Abstract][Full Text] [Related]
30. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288 [TBL] [Abstract][Full Text] [Related]
31. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534 [TBL] [Abstract][Full Text] [Related]
32. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692 [TBL] [Abstract][Full Text] [Related]
33. Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. Okamoto I; Nokihara H; Nomura S; Niho S; Sugawara S; Horinouchi H; Azuma K; Yoneshima Y; Murakami H; Hosomi Y; Atagi S; Ozaki T; Horiike A; Fujita Y; Okamoto H; Ando M; Yamamoto N; Ohe Y; Nakagawa K JAMA Oncol; 2020 May; 6(5):e196828. PubMed ID: 32163097 [TBL] [Abstract][Full Text] [Related]
34. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH; Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591 [TBL] [Abstract][Full Text] [Related]
35. An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. Yadav A; Malik PS; Khurana S; Jain D; Vishnubhatla S; Yadav M; Pathy S; Mohan A; Kumar L Oncology; 2021; 99(6):389-396. PubMed ID: 33735884 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635 [TBL] [Abstract][Full Text] [Related]
37. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Ito M; Horita N; Nagashima A; Kaneko T Asia Pac J Clin Oncol; 2019 Apr; 15(2):e3-e10. PubMed ID: 29316288 [TBL] [Abstract][Full Text] [Related]